Sign in

Vinny Pizzuti, MD, MS

@vpizzuti.bsky.social
81 followers 80 following 15 posts

IM PGY3 at University of Colorado, Rising Chief Medical Resident ‘26-‘27, Future Heme/onc Hopeful, Former Engineer. He/him

PostsRepliesMedia
Reposted by Vinny Pizzuti, MD, MS
CU Anschutz Cancer Center @cucancercenter.bsky.social · 03/09/2026
In a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF
Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.
073
Reposted by Vinny Pizzuti, MD, MS
Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...
162
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 04/08/2026
Grateful to @majorajay.bsky.social and all of our collaborators for the guidance and efforts for this paper! Excited to share these results
000
Reposted by Vinny Pizzuti, MD, MS
Ajay Major, MD, MBA @majorajay.bsky.social · 04/08/2026
Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org. CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."
232
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 16/07/2025
I am happy to announce I was selected by @ash.hematology.org to receive the ASH HONORS Award! Excited for this project studying PET/CT radiomics in DLBCL. Grateful to Dr. Manali Kamdar for her mentorship & ASH! #ASHAwards #Fight4Hematology @cudeptofmedicine.bsky.social @cuhematology.bsky.social
161
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
@majorajay.bsky.social
010
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
@cuhematology.bsky.social @cudeptofmedicine.bsky.social
000
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Be on the lookout for a manuscript next year further describing our work! Big thanks to @ASH_hematology for allowing me to present and my mentor @majorajay for all the guidance and support! Check out for more info: - ashpublications.org/blood/article/… - bison-pro.org
210
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
We plan to further expand this work by modeling pt cohorts at higher risk for inferior QoL outcomes, using the heatmap model to potentially detect those pts at risk for relapse/tx failure, and further examining the impact of novel txs in different disease states #ASH24 /9
110
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Taken together, this proof-of-principle study demonstrates we can successfully utilize the BISON-PRO study group to detect meaningful differences between groups of lymphoma pts receiving different treatments/monitoring #ASH24 /8
110
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Similar improvements in reducing negative QoL outcomes were observed for active treatment groups at 6 months. Pts receiving cell therapies had temporary worsening of anxiety/depression early in tx but did have improvement in fatigue in our cohort #ASH24 /7
120
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
For the positive outcomes, surveillance pts saw minimal changes from 0 to 6 months. Pts receiving systemic tx or cell therapies had overall improved measures at 6 mos., but pts receiving chemo had worsened cognitive function at 6 months #ASH24 /6
110
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Once we observed these differences, we used these PROMIS T-scores to calculate percentiles and use the relative change in T-score percentiles from baseline to various time points to construct a heatmap model of positive and negative QoL measures #ASH24 /5
110
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Similarly, PROMIS instruments were able to detect differences between groups, and here we highlight that global physical health and role functioning were higher in patients undergoing active surveillance vs active tx #ASH24 /4
120
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Using FACT instruments, we observed significant differences between groups at baseline for lymphoma pts. Interestingly, QoL seemingly improved for pts with lymphoma undergoing active tx (FACT-LYM), but this was not seen with CLL pts (FACT-LEU) #ASH24 /3
120
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
In our initial feasibility study, we administered PROMIS and FACT instruments to patients in 3 arms longitudinally and sought to determine if we could detect meaningful differences between study groups #ASH24 /2
110
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 18/12/2024
Interested in patient reported outcomes (PROs) in patients with lymphoma? Join me as I recap my poster highlighting our work on the BISON PRO QoL Study presented at #ASH24 #lymsm
181
Vinny Pizzuti, MD, MS @vpizzuti.bsky.social · 10/12/2024
Really grateful to have had the opportunity to present a poster highlighting my work with @majorajay.bsky.social at #ASH2024 it was a great experience with a great group of people!
291
Reposted by Vinny Pizzuti, MD, MS
Ajay Major, MD, MBA @majorajay.bsky.social · 09/12/2024
Sneak peek of my mentee Dr. Pizzuti's heatmap PRO analysis PROs from our BISON-PRO Quality of Life Study (bison-pro.org). His abstract is at tonight's #ASH24 poster session; big congrats on his ASH Achievement Award! #MajorPROsASH cc @cuhematology.bsky.social @vpizzuti.bsky.social
071